Ipsen Logo

Ipsen

Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.

IPN | PA

Overview

Corporate Details

ISIN(s):
FR0010259150 (+17 more)
LEI:
549300M6SGDPB4Z94P11
Country:
France
Address:
65 QUAI GEORGES GORSE, 92100 BOULOGNE-BILLANCOURT
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ipsen is a global biopharmaceutical company focused on developing and commercializing innovative medicines in specialty care. The company concentrates its efforts on three key therapeutic areas: Oncology, Rare Diseases, and Neuroscience. Ipsen's strategy targets conditions with high unmet medical needs, leveraging its global infrastructure, scientific expertise, and strategic partnerships to accelerate its research pipeline and bring transformative treatments to patients worldwide. The company is committed to advancing science with the purpose of improving health outcomes for underserved patient populations.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-07 18:30
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 84.4 KB
2025-10-07 18:30
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2025
English 85.2 KB
2025-09-30 18:30
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025
English 81.9 KB
2025-09-30 18:30
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 81.3 KB
2025-09-16 18:30
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 86.5 KB
2025-09-16 18:30
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2025
English 86.4 KB
2025-09-02 18:00
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 269.9 KB
2025-09-02 18:00
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025
English 542.0 KB
2025-07-10 18:30
Declaration of Voting Results & Voting Rights Announcements
Ipsen - Juin 2025 - Information mensuelle relative au nombre total des droits d…
French 124.2 KB
2025-07-10 18:30
Declaration of Voting Results & Voting Rights Announcements
Ipsen - June 2025 - Monthly information relative to the total number of voting …
English 106.7 KB
2025-07-01 09:00
Environmental & Social Information
Gemeinsam fur eine bessere Zukunft: Ipsen Pharma GmbH engagiert sich am Communi…
German 8.6 KB
2025-06-17 18:00
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025
English 271.6 KB
2025-06-17 18:00
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 468.0 KB
2025-06-13 18:00
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025
English 324.3 KB
2025-06-13 18:00
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 293.1 KB

Automate Your Workflow. Get a real-time feed of all Ipsen filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ipsen

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ipsen via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-04 N/A Other Sell 850 91,374.66 EUR
2024-02-27 N/A Other Buy 500 51,916.20 EUR
2023-07-31 N/A Other Buy 50,048 N/A

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.